Rationale
-
LSD1 is essential for cancer stem cell survival and maintenance of AML blasts. Both LSD1 and HDAC6 lead to immune suppression through distinct mechanisms
-
Both targets are over-expressed in AML and multiple other cancers
-
LSD1 and HDAC6 are part of co-repressor complexes leading to modulation of cancer-specific genes
-
Current SoCs for AML have a low response rate, limited single agent activity and dose-limiting toxicities
-
Novel therapies targeting multiple pathways are beneficial
-
LSD1 inhibitors alone have shown limited single agent activity
-
Selective inhibition of HDAC6 may reduce the toxicity associated with pan-HDAC inhibitors

The transcriptional corepressor complex CoREST contains multiple proteins including demethylase (LSD1) and deacetylases (HDAC) that regulate the gene expression. Dual LSD1/HDAC6 inhibitor comprehensively blocks the CoREST complex, to show a unique pharmacologic action relative to HDAC or LSD1 inhibitors.